An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

Trial Profile

An Open-Label Study Of Poly I:Poly C12U (AMPLIGEN) in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 10 Jul 2018

At a glance

  • Drugs Rintatolimod (Primary)
  • Indications Chronic fatigue syndrome; Encephalomyelitis
  • Focus Adverse reactions; Expanded access; Registrational
  • Sponsors Hemispherx Biopharma
  • Most Recent Events

    • 28 Jun 2018 Status changed from active, no longer recruiting to recruiting.
    • 27 Jun 2018 According to a Hemispherx Biopharma media release, this trial will enrol new patients at Hunter-Hopkins Center, North Carolina and Sierra Internal Medicine in Nevada.
    • 21 Jul 2017 Planned End Date changed from 1 Feb 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top